

Draft Guidance on Elbasvir; Grazoprevir

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Elbasvir; Grazoprevir

Dosage Form; Route: Tablet; oral

Recommended Studies: Two studies

1. Type of study: Fasting
Design: Single-dose, two-way crossover *in-vivo*
Strength: 50 mg; 100 mg
Subjects: Healthy males and non-pregnant females, general population.
Additional Comments: None

2. Type of study: Fed
Design: Single-dose, two-way crossover *in-vivo*
Strength: 50 mg; 100 mg
Subjects: Healthy males and non-pregnant females, general population.
Additional comments: None

Analytes to measure (in appropriate biological fluid): Elbasvir and Grazoprevir in plasma

Bioequivalence based on (90% CI): Elbasvir and Grazoprevir

Waiver request of in-vivo testing: N/A

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website available to the public at the following location: <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).